Gene therapy clinical trials worldwide 1989-2004 - an overview

被引:265
作者
Edelstein, ML
Abedi, MR
Wixon, J [1 ]
Edelstein, RM
机构
[1] John Wiley & Sons Ltd, Life & Med Sci, Chichester PO19 8SQ, W Sussex, England
[2] Karolinska Univ Hosp, SE-14186 Stockholm, Sweden
[3] Univ Birmingham, Sch Med, Birmingham B15 2TT, W Midlands, England
关键词
gene therapy; clinical trials;
D O I
10.1002/jgm.619
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In 1989, Rosenberg et al. performed the first human gene therapy trial when they used a retrovirus to introduce the gene coding for resistance to neomycin into human tumor-infiltrating lymphocytes before infusing them into five patients with advanced melanoma. This study demonstrated the feasibility of using retroviral gene transduction in humans and set the stage for further studies. Since then, over 900 clinical trials have been completed, are ongoing or have been approved worldwide. These trials have been designed to establish feasibility and safety, to demonstrate the reality of expression of therapeutic protein(s) in vivo by the genes transferred and, in some cases, to show therapeutic benefit. There is no single source of information that presents an overview of all the clinical trials undertaken worldwide. In 1997 we set up a database to bring all the information on clinical trials together as comprehensively and as globally as possible. The data were compiled and are regularly updated from official agency sources, the published literature, presentations at conferences and from information kindly provided by investigators or trial sponsors themselves. As of January 31, 2004, we have identified 918 trials in 24 countries. The USA accounts for two-thirds of these trials. Cancer is by far the most common disease indication, followed by inherited monogenic diseases, and cardiovascular diseases. Viral vectors have been the most frequently used vehicles for transferring genes into human cells, with retroviruses and adenoviruses representing the vast majority. Plasmid (naked) DNA and other non-viral vectors have been used in one-quarter of the trials. Over 100 distinct genes have been transferred. This article aims to provide a descriptive overview of the clinical trials that, to the best of our knowledge, have been or are being performed worldwide. Details of the data presented, including an interactive, searchable database that currently holds information on 918 trials, can be found on The Journal of Gene Medicine clinical trials website [1]. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:597 / 602
页数:6
相关论文
共 17 条
  • [1] T-LYMPHOCYTE-DIRECTED GENE-THERAPY FOR ADA(-) SCID - INITIAL TRIAL RESULTS AFTER 4 YEARS
    BLAESE, RM
    CULVER, KW
    MILLER, AD
    CARTER, CS
    FLEISHER, T
    CLERICI, M
    SHEARER, G
    CHANG, L
    CHIANG, YW
    TOLSTOSHEV, P
    GREENBLATT, JJ
    ROSENBERG, SA
    KLEIN, H
    BERGER, M
    MULLEN, CA
    RAMSEY, WJ
    MUUL, L
    MORGAN, RA
    ANDERSON, WF
    [J]. SCIENCE, 1995, 270 (5235) : 475 - 480
  • [2] Human tumor antigens recognized by T lymphocytes
    Boon, T
    vanderBruggen, P
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) : 725 - 729
  • [3] Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
    Cavazzana-Calvo, M
    Hacein-Bey, S
    Basile, CD
    Gross, F
    Yvon, E
    Nusbaum, P
    Selz, F
    Hue, C
    Certain, S
    Casanova, JL
    Bousso, P
    Le Deist, F
    Fischer, A
    [J]. SCIENCE, 2000, 288 (5466) : 669 - 672
  • [4] Cavazzana-Calvo M, 2001, J GENE MED, V3, P201, DOI 10.1002/1521-2254(200105/06)3:3<201::AID-JGM195>3.0.CO
  • [5] 2-Z
  • [6] Harmful potential of viral vectors fuels doubts over gene therapy
    Check, E
    [J]. NATURE, 2003, 423 (6940) : 573 - 574
  • [7] Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID) - Position of the European Society of Gene Therapy (ESGT)
    Gansbacher, B
    [J]. JOURNAL OF GENE MEDICINE, 2003, 5 (03) : 261 - 262
  • [8] Policy statement on the social, ethical and public awareness issues in gene therapy
    Gänsbacher, B
    [J]. JOURNAL OF GENE MEDICINE, 2002, 4 (06) : 687 - 691
  • [9] LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1
    Hacein-Bey-Abina, S
    Von Kalle, C
    Schmidt, M
    McCcormack, MP
    Wulffraat, N
    Leboulch, P
    Lim, A
    Osborne, CS
    Pawliuk, R
    Morillon, E
    Sorensen, R
    Forster, A
    Fraser, P
    Cohen, JI
    de Saint Basile, G
    Alexander, I
    Wintergerst, U
    Frebourg, T
    Aurias, A
    Stoppa-Lyonnet, D
    Romana, S
    Radford-Weiss, I
    Gross, F
    Valensi, F
    Delabesse, E
    Macintyre, E
    Sigaux, F
    Soulier, J
    Leiva, LE
    Wissler, M
    Prinz, C
    Rabbitts, TH
    Le Deist, F
    Fischer, A
    Cavazzana-Calvo, M
    [J]. SCIENCE, 2003, 302 (5644) : 415 - 419
  • [10] A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
    Hacein-Bey-Abina, S
    von Kalle, C
    Schmidt, M
    Le Deist, F
    Wulffraat, N
    McIntyre, E
    Radford, I
    Villeval, JL
    Fraser, CC
    Cavazzana-Calvo, M
    Fischer, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03) : 255 - 256